Prof Research published a new market report on the flu vaccine. It presents the largest 6 manufacturers in the flu vaccine Market. The report is a professional and in-depth study on the current state of the global flu vaccine market with a focus on the Chinese market. The report provides key statistics on the market for the flu vaccine. It is a valuable source of guidance and direction for companies and individuals interested in the flu vaccine industry.

The global flu vaccine market was valued to be 7,271 million USD in 2020. The flu vaccine production value is anticipated to grow with a CAGR of 7.65% in the coming years to reach 11,313 million USD in 2026.

Sanofi is the largest manufacturer of flu vaccine in the world, it has a market share of 42.7% in value. Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in therapeutic solutions research, development, manufacture, and marketing. Its three operating segments are Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines.

CSL is the second-largest manufacturer of flu vaccine in the world, it has a market share of 18.9% in value. CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus.

GSK is the third-largest manufacturer of flu vaccine in the world, it has a market share of 12.8% in value. GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products.

Viatris is the fourth largest manufacturer of flu vaccine in the world, it has a market share of 4.1% in value. Mylan is now part of Viatris Inc., a new global healthcare company committed to empowering people to live healthier at every stage of life. Viatris Inc. has four segments: Developed Markets, Greater China, JANZ and Emerging Markets.